Show simple item record

dc.contributor.authorMcDonald, F
dc.contributor.authorDe Waele, M
dc.contributor.authorHendriks, L
dc.contributor.authorFaivre-Finn, Corinne
dc.contributor.authorDingemans, A
dc.contributor.authorVan Schil, P
dc.date.accessioned2017-01-31T16:14:24Z
dc.date.available2017-01-31T16:14:24Z
dc.date.issued2017-01
dc.identifier.citationManagement of stage I and II nonsmall cell lung cancer. 2017, 49(1): Eur Respir Jen
dc.identifier.issn1399-3003
dc.identifier.pmid28049169
dc.identifier.doi10.1183/13993003.00764-2016
dc.identifier.urihttp://hdl.handle.net/10541/620109
dc.description.abstractThe incidence of stage I and II nonsmall cell lung cancer is likely to increase with the ageing population and introduction of screening for high-risk individuals. Optimal management requires multidisciplinary collaboration. Local treatments include surgery and radiotherapy and these are currently combined with (neo)adjuvant chemotherapy in specific cases to improve long-term outcome. Targeted therapies and immunotherapy may also become important therapeutic modalities in this patient group. For resectable disease in patients with low cardiopulmonary risk, complete surgical resection with lobectomy remains the gold standard. Minimally invasive techniques, conservative and sublobar resections are suitable for a subset of patients. Data are emerging that radiotherapy, especially stereotactic body radiation therapy, is a valid alternative in compromised patients who are high-risk candidates for surgery. Whether this is also true for good surgical candidates remains to be evaluated in randomised trials. In specific subgroups adjuvant chemotherapy has been shown to prolong survival; however, patient selection remains important. Neoadjuvant chemotherapy may yield similar results as adjuvant chemotherapy. The role of targeted therapies and immunotherapy in early stage nonsmall cell lung cancer has not yet been determined and results of randomised trials are awaited.
dc.language.isoenen
dc.rightsArchived with thanks to The European respiratory journalen
dc.titleManagement of stage I and II nonsmall cell lung cancer.en
dc.typeArticleen
dc.contributor.departmentDept of Radiotherapy, Royal Marsden NHS Foundation Trust, Sutton, UKen
dc.identifier.journalThe European Respiratory Journalen
refterms.dateFOA2020-04-21T09:03:33Z
html.description.abstractThe incidence of stage I and II nonsmall cell lung cancer is likely to increase with the ageing population and introduction of screening for high-risk individuals. Optimal management requires multidisciplinary collaboration. Local treatments include surgery and radiotherapy and these are currently combined with (neo)adjuvant chemotherapy in specific cases to improve long-term outcome. Targeted therapies and immunotherapy may also become important therapeutic modalities in this patient group. For resectable disease in patients with low cardiopulmonary risk, complete surgical resection with lobectomy remains the gold standard. Minimally invasive techniques, conservative and sublobar resections are suitable for a subset of patients. Data are emerging that radiotherapy, especially stereotactic body radiation therapy, is a valid alternative in compromised patients who are high-risk candidates for surgery. Whether this is also true for good surgical candidates remains to be evaluated in randomised trials. In specific subgroups adjuvant chemotherapy has been shown to prolong survival; however, patient selection remains important. Neoadjuvant chemotherapy may yield similar results as adjuvant chemotherapy. The role of targeted therapies and immunotherapy in early stage nonsmall cell lung cancer has not yet been determined and results of randomised trials are awaited.


Files in this item

Thumbnail
Name:
559188.pdf
Size:
339.1Kb
Format:
PDF
Description:
From UNPAYWALL

This item appears in the following Collection(s)

Show simple item record